Primary outcomes included hematoma volume, serum MMP2/MMP9 levels, neurological function (NIHSS), quality of life (ADL), and prognosis (GOS).<h4>Results</h4>After 2 weeks of treatment, the pregabalin group showed significantly smaller hematoma volume compared with the control group (p < 0.01). This evidence concerns the gene MMP2 and hematoma.